- Home
- NEWS
- REGIONAL
- THIS WEEK'S PAPER
- BLOGS
- Multimedia
- OPINION
- A&E
- LISTS
- PEOPLE
- EVENTS
- Classifieds
- Subscribe
BioCrossroads
Mobile health apps could cut into state companies' market share
May 18, 2013
J.K. WallThe future of Indiana’s sprawling health care and life sciences industry might be threatened by an unlikely source:
smartphone apps.
MorePANEL: Life sciences will see radically different future
May 17, 2013
IBJ convened a panel of experts at its Life Sciences Power Breakfast on May 10 to talk about the industry issues
of venture capital, digital health innovations and research university entrepreneurship.
MorePanel members included Kristin Eilenberg, CEO, Lodestone Logic, Infuse Accelerator; Philip S. Low, Purdue University professor of chemistry, founder and chief science officer at Endocyte Inc. and On Target Laboratories LLC; R. Matthew Neff, president, CHV Capital Inc.; Brian Stemme, project director; BioCrossroads; Brian S. Williams, director, Global Healthcare Strategy, PricewaterhouseCoopers International Ltd.; and Raul Zaveleta, CEO, Indigo BioSystems Inc.
The following is an unedited transcript of the discussion.
Indiana officials look to boost agriculture research
February 3, 2013
Associated PressThe state's agriculture department under new Gov. Mike Pence is planning a push into the science behind food production
by trying to build a network of university and commercial researchers for what's being called an Agriculture Innovation
Corridor.
MoreHealth care startups hungry for funds
February 2, 2013
J.K. WallFrustrated by up-and-down state funding for startup life sciences companies, industry leaders are talking up a plan to create
a dedicated funding stream that could total $30 million a year.
MoreBioCrossroads: Life sciences a $50B industry in Indiana
January 22, 2013
J.K. WallThe life sciences industry in Indiana employs 55,500 workers paying average wages of more than $88,500 per year, according
to new figures released Tuesday by Indianapolis-based life sciences development group BioCrossroads.
MoreBioCrossroads seed fund makes first investments
January 10, 2013
Local startups Esanex Inc. and Algaeon Inc. have received $500,000 and $250,000, respectively, from Indiana Seed Fund II,
BioCrossroads' second fund to help fledgling life sciences companies.
MoreJohnson picked to succeed Miles as leader of CICP
December 18, 2012
IBJ StaffBioCrossroads CEO David Johnson has been chosen president and CEO of the Central Indiana Corporate Partnership, succeeding
Mark Miles, who is leaving the CICP after seven years to become CEO of Hulman & Co.
MoreLife sciences leader juggles faith, science and business
November 3, 2012
J.K. WallBioCrossroads CEO David Johnson sees little conflict as he balances all three in promoting and investing in Indiana life sciences
firms
MoreOutlook gloomy for device investments
October 29, 2012
J.K. WallThe amount of venture capital invested in medical-device and equipment companies nationally has declined each quarter this
year, reaching levels not seen since 2004, according to data released Oct. 19 by the National Venture Capital Association
and PricewaterhouseCoopers.
MoreLilly CEO calls for life sciences research institute
October 23, 2012
J.K. WallEli Lilly CEO John Lechleiter on Tuesday called for creation of a "world-class" research institute in Indianapolis to bring
together scientists from universities and corporations to develop new medical therapies and companies.
MoreNext up for Indiana biotech: Feed the world
August 6, 2012
J.K. WallEven though the potential payoff for health care innovation is less certain these days, the business case for new ways to
produce more food has never been stronger. That’s the analysis that lies behind BioCrossroads' new report an agricultural
innovation.
MoreIndiana life sciences companies rethink innovation
July 28, 2012
J.K. WallResearch and development comes under pressure in an age of austerity.
MoreLife sciences hold up in recession
June 25, 2012
J.K. WallA new report shows Indiana’s life sciences companies performed better than their peers around the country—and
far better than the rest of Indiana’s private sector—during the early phases of the economic downturn.
MoreBioCrossroads launches second seed fund
April 30, 2012
J.K. WallBioCrossroads Inc. has raised an $8.25 million seed fund in its second attempt to help startup life sciences companies grow
to the point where they can attract venture capital or a corporate funder.
MoreBioCrossroads has stoked state's life sciences industry, but challenges remain
February 11, 2012
J.K. WallIn the 10 years BioCrossroads has been promoting life sciences in Indiana, the effort has netted more than 330 new companies,
an infusion of more than $330 million in venture capital, a tripling of exports, and a growing number of mentions in national
reports on life sciences.
MoreHealth care VC hits new Indiana low in 2011
February 6, 2012
J.K. WallIndiana companies landed just $14.1 million in venture funding last year, the lowest amount of capital flowing to the
state’s health care sector since BioEnterprises began tracking such deals in 2005.
MoreIndiana's medical device workforce will need skills upgrade
January 14, 2012
J.K. WallA new report by BioCrossroads says 53 percent of the 20,000 jobs in Indiana’s medical-device sector require no more
than a high school education.
MoreBioCrossroads seeds upstart medical device maker
October 20, 2011
Chris O'MalleyBioCrossroads’ Indiana Seed Fund has invested $300,000 in a startup company chaired by a former Eli Lilly and Co. executive
developing an absorbable stent.
MoreBiocrossroads lands $2.8 million Lilly Endowment grant
October 8, 2011
IBJ StaffThe advocate for the state's life sciences industry has now pulled in more than $25 million from the endowment.
MoreMore life sciences firms opt to launch products in Europe
July 30, 2011
Maria LaMagnaThe U.S. Food and Drug Administration's growing reputation for unpredictability is spurring some Indianapolis companies to
join counterparts elsewhere and introduce products in Europe. The upshot is that some Americans may never benefit from innovations
occurring in their backyards.
MoreIndiana life sciences leaders look toward the future
July 30, 2011
Chris O'MalleyFormer Eli Lilly and Co. vice president Richard Dimarchi, BioCrossroads President David Johnson, angel investor Oscar Moralez
and Purdue University Senior Vice President Alan Rebar discuss issues ranging from the depth of the life sciences industry
in Indiana to venture capital and Purdue's Discovery Park.
MoreTech district could boost Indianapolis' convention business
July 23, 2011
Scott OlsonThe Indianapolis Convention & Visitors Association plans to attract more life sciences conferences.
MoreReport: State's life science sector continues to grow
June 23, 2011
Chris O'MalleyA total of 220 life sciences startups have been launched in Indiana since 2004, or an average of 44 per year, according to
a new report from BioCrossroads that tracked the industry’s growth over the last eight years.
MoreLilly licenses Xigris rights to new biotech firm
May 23, 2011
J.K. WallEli Lilly and Co. has agreed to license the U.S. marketing rights of its slow-selling sepsis drug Xigris to a newly created
local biotech company called BioCritica that will seek to reinvigorate sales of the medication.
MoreBISHOP: Warsaw's orthopedics whizzes will master biologics
May 14, 2011
Industry cluster in northern Indiana has adapted to every other change in health care, and will absorb tissue regeneration,
too.
More
Sponsored by
ADVERTISEMENT
on Facebook & Twitter
on Facebook & Twitter
 Follow IBJ's Tweets on these topics: |
||
| @IBJNews | @Propertylines | @IBJTheScore |
| @IBJArts | @IBJHealthcare | @IBJDining |
| @IBJLists | @IBJSmallbiz | |
ADVERTISEMENT
Back to TopCopyright © All Rights Reserved. Privacy Policy | Terms of Use.
Design, CMS, Hosting & Web Development :: ePublishing.
Additional Hosting & Delivery by
First, the Athenaeum is going to have to get past the hurdle with the Lockerbie residents and the agreement that the parcel would be residential. Second, and in my opinion, this prime piece of property should include parking, PLUS, a black box theater(s), some market rate and affordable artist housing and a plan to renovate and reconfigure the second story theater. I would negotiate to add the DeHaan property surface parking lot into the development mix, place a one story surface parking garage on the DeHaan lot on the street level (for the Dehaan tenants use during the daytime) and add a second story to the garage that would become an addition to the current second story theater and then change the direction of the theater by moving the stage across the alley and on top of the DeHaan lot parking. You can add all the stage elements that are currently missing from the Athenaeum stage to make it more attractive for use by Ballet, Opera and traveling productions. Plus, the theater changes would probably help solve some of the soundproofing issues. Alas,it does not seem to be a part of the strategic plan to conduct a study to determine best use of the property. Seems like the current plan is a quick and easy move that ignores the property best use/potential and any strategic property planning for the effect on future generations.
I recall that MSA's pilings are still in the ground and hard to remove. It’s not likely any proposal will include significant underground construction/parking because of this. Start adding 2 floors of retail, 8 floors of parking and 5-10 floors of possible hotel, and/or 10-20 floors of residential, and you are at 30 floors already with possible expansion of all the uses. But then again I could be wrong.
Accoriding to their website there is no deadline to the Do Not Call list. What is this article referring to??
On what planet are they entitled to this largesse from the stockholders? These people make multi-million dollar salaries: Pay for your own personal travel.
It matters because they're already paid enormously fat salaries: Pay for your own personal travel. Being "taxed on it" isn't a valid excuse--so what? They're still being gifted a raft of luxury perks from somebody else's money on top of an enormous, lavish salary.